Matches in SemOpenAlex for { <https://semopenalex.org/work/W2305284500> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W2305284500 abstract "Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PAHER2-targeting therapies transformed the treatment of patients with HER2+ breast cancer and are now being explored in other cancer types. However, nearly 70% of patients with HER2+ metastatic breast cancer have intrinsic resistance and almost all develop acquired resistance to HER2-targeting drugs. New therapeutic approaches aimed at resistance to HER2-targeting therapies are urgently needed. We have previously found that resistance to HER2-targeting drugs involves increased activity of the phosphatase PP2A. PP2A was reported to stimulate the kinase activity of CDK8, a transcription-regulating kinase that in contrast to some other members of the CDK family does not regulate cell cycle progression. Thus CDK8 may play a role in resistance to HER2-targeting therapies. CDK8 has been identified as an oncogene amplified in 50% of colon cancers. Immunohistochemical staining of breast tissue arrays and meta-analysis of breast cancer microarray data revealed that CDK8 is overexpressed in breast cancers and that higher CDK8 expression correlates with the failure of systemic therapy. Selective small-molecule inhibitors of CDK8 and its paralog CDK19 show no limiting toxicities at therapeutically effective doses. We have found that an optimized CDK8/19 inhibitor Senexin B has a synergistic growth-inhibitory effect in combinations with an anti-HER2 monoclonal antibody (a biosimilar of trastuzumab) and with the HER2/EGFR small-molecule inhibitor lapatinib. These synergistic effects were observed in all HER2+ breast and colon cancer cell lines tested so far, including those that are either sensitive to HER2-targeting drugs or non-responsive to these agents due to innate or acquired resistance. Furthermore, combining lapatinib with Senexin B inhibited the development of de novo resistance to lapatinib. Taken together these results suggest that combining anti-HER2 and anti-CDK8 therapies is a rational potential treatment for HER2+ cancers, which may overcome both innate and acquired resistance to HER2-targeting drugs.Citation Format: Martina McDermott, Laura Ivers, Norma O'Donovan, John Crown, Igor Roninson, Eugenia V. Broude. Overcoming resistance to HER2-targeting drugs using CDK8 inhibitors. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 5459. doi:10.1158/1538-7445.AM2015-5459" @default.
- W2305284500 created "2016-06-24" @default.
- W2305284500 creator A5000509598 @default.
- W2305284500 creator A5006208805 @default.
- W2305284500 creator A5021160836 @default.
- W2305284500 creator A5043292277 @default.
- W2305284500 creator A5049867556 @default.
- W2305284500 creator A5070188926 @default.
- W2305284500 date "2015-08-01" @default.
- W2305284500 modified "2023-09-26" @default.
- W2305284500 title "Abstract 5459: Overcoming resistance to HER2-targeting drugs using CDK8 inhibitors" @default.
- W2305284500 doi "https://doi.org/10.1158/1538-7445.am2015-5459" @default.
- W2305284500 hasPublicationYear "2015" @default.
- W2305284500 type Work @default.
- W2305284500 sameAs 2305284500 @default.
- W2305284500 citedByCount "0" @default.
- W2305284500 crossrefType "proceedings-article" @default.
- W2305284500 hasAuthorship W2305284500A5000509598 @default.
- W2305284500 hasAuthorship W2305284500A5006208805 @default.
- W2305284500 hasAuthorship W2305284500A5021160836 @default.
- W2305284500 hasAuthorship W2305284500A5043292277 @default.
- W2305284500 hasAuthorship W2305284500A5049867556 @default.
- W2305284500 hasAuthorship W2305284500A5070188926 @default.
- W2305284500 hasConcept C121608353 @default.
- W2305284500 hasConcept C124320809 @default.
- W2305284500 hasConcept C126322002 @default.
- W2305284500 hasConcept C2775930923 @default.
- W2305284500 hasConcept C2777329042 @default.
- W2305284500 hasConcept C2779786085 @default.
- W2305284500 hasConcept C2779998722 @default.
- W2305284500 hasConcept C29537977 @default.
- W2305284500 hasConcept C2994294914 @default.
- W2305284500 hasConcept C502942594 @default.
- W2305284500 hasConcept C526805850 @default.
- W2305284500 hasConcept C530470458 @default.
- W2305284500 hasConcept C71924100 @default.
- W2305284500 hasConcept C98274493 @default.
- W2305284500 hasConceptScore W2305284500C121608353 @default.
- W2305284500 hasConceptScore W2305284500C124320809 @default.
- W2305284500 hasConceptScore W2305284500C126322002 @default.
- W2305284500 hasConceptScore W2305284500C2775930923 @default.
- W2305284500 hasConceptScore W2305284500C2777329042 @default.
- W2305284500 hasConceptScore W2305284500C2779786085 @default.
- W2305284500 hasConceptScore W2305284500C2779998722 @default.
- W2305284500 hasConceptScore W2305284500C29537977 @default.
- W2305284500 hasConceptScore W2305284500C2994294914 @default.
- W2305284500 hasConceptScore W2305284500C502942594 @default.
- W2305284500 hasConceptScore W2305284500C526805850 @default.
- W2305284500 hasConceptScore W2305284500C530470458 @default.
- W2305284500 hasConceptScore W2305284500C71924100 @default.
- W2305284500 hasConceptScore W2305284500C98274493 @default.
- W2305284500 hasLocation W23052845001 @default.
- W2305284500 hasOpenAccess W2305284500 @default.
- W2305284500 hasPrimaryLocation W23052845001 @default.
- W2305284500 hasRelatedWork W1608985719 @default.
- W2305284500 hasRelatedWork W189635737 @default.
- W2305284500 hasRelatedWork W1989116686 @default.
- W2305284500 hasRelatedWork W1997056190 @default.
- W2305284500 hasRelatedWork W2033425661 @default.
- W2305284500 hasRelatedWork W2080550759 @default.
- W2305284500 hasRelatedWork W2396317271 @default.
- W2305284500 hasRelatedWork W2565658677 @default.
- W2305284500 hasRelatedWork W2627019357 @default.
- W2305284500 hasRelatedWork W2739844710 @default.
- W2305284500 hasRelatedWork W2772424151 @default.
- W2305284500 hasRelatedWork W2954998569 @default.
- W2305284500 hasRelatedWork W2955157624 @default.
- W2305284500 hasRelatedWork W2971050114 @default.
- W2305284500 hasRelatedWork W2995918299 @default.
- W2305284500 hasRelatedWork W3027984788 @default.
- W2305284500 hasRelatedWork W3036786989 @default.
- W2305284500 hasRelatedWork W3049108467 @default.
- W2305284500 hasRelatedWork W3132036750 @default.
- W2305284500 hasRelatedWork W3214371973 @default.
- W2305284500 isParatext "false" @default.
- W2305284500 isRetracted "false" @default.
- W2305284500 magId "2305284500" @default.
- W2305284500 workType "article" @default.